Skip to main content
Book cover

Orofacial Supportive Care in Cancer pp 23–38Cite as

Solid Tumours and Update on Modern Medical Oncology Interventions

  • 93 Accesses

Abstract

Systemic therapy for head and neck cancers has been successfully used as single agents or combinations of agents for palliation of recurrent or metastatic disease. It can be used concomitantly with radiation therapy for definitive local therapy or relapse and for adjuvant therapy post-surgery. Chemotherapy has been the mainstay of systemic treatment, but modern interventions are incorporating immunotherapy in the form of monoclonal antibodies or checkpoint inhibitors to be added to current chemotherapy regimens.

Keywords

  • Head and neck
  • Chemotherapy
  • Immunotherapy
  • Radiotherapy
  • Chemoradiotherapy
  • Monoclonal antibodies
  • Checkpoint inhibitors

This is a preview of subscription content, access via your institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-3-030-86510-8_3
  • Chapter length: 16 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   139.00
Price excludes VAT (USA)
  • ISBN: 978-3-030-86510-8
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Hardcover Book
USD   179.99
Price excludes VAT (USA)
Learn about institutional subscriptions

Bibliography

  1. Gold KA, Neskey M, William WN. The role of systemic treatment before, during, and after definitive treatment. Otolaryngol Clin N Am. 2013;46:645–56.

    Google Scholar 

  2. Kelly CG. Chemotherapy: United Kingdom National multidisciplinary guidelines. J Laryngol Otol. 2016;130(Suppl 2):S71–4.

    PubMed  PubMed Central  Google Scholar 

  3. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data form a phase III randomized trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11:21–8.

    PubMed  Google Scholar 

  4. Mehra R, Seiwer TY, Gupta S, Weiss J, Gluck I, Eder JP, et al. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. Br J Cancer. 2018;119:153–9.

    PubMed  PubMed Central  Google Scholar 

  5. Yue Q, Zhang M, Chen Y, Zheng D, Chen Y, Feng M. Establishment of prognostic factors in recurrent nasopharyngeal carcinoma patients who received salvage intensity-modulated radiotherapy: a meta-analysis. Oral Oncol. 2018;81:81–8.

    PubMed  Google Scholar 

  6. Solomon B, Young RJ, Rischin D. Head and neck squamous cell carcinoma: genomics and emerging biomarkers for immunomodulatory cancer treatments. Semin Cancer Biol. 2018; https://doi.org/10.1016/j.semcancer.2018.01.008. [Epub ahead of print].

  7. Bonner JA, Mesia R, Giralt J, Psyrri A, Keilholz U, Rosenthal DI, et al. p19, HPV, and cetuximab: what is the evidence? Oncologist. 2017;22:811–22.

    PubMed  PubMed Central  Google Scholar 

  8. Smith IE, Harrris AL, Morgan M, Ford HT, Gazet JC, Harmer CL, et al. Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial. Br Med J (Clin Res Ed). 1981;283:1432–4.

    Google Scholar 

  9. International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature. 2001;409:860–921.

    Google Scholar 

  10. Shendure J, Hanlee J. Next-generation DNA sequencing. Nat Biotechnol. 2008;26:1135–45.

    PubMed  Google Scholar 

  11. Broach JR, Thorner J. High-throughput screening for drug discovery. Nature. 1996;384(Suppl):14–6.

    PubMed  Google Scholar 

  12. Drucker BJ, Guilhot F, O’Brien SG, Gatmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408–17.

    Google Scholar 

  13. Eggermont AMM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer. 2004;40:1825–36.

    PubMed  Google Scholar 

  14. McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15:323–32.

    PubMed  PubMed Central  Google Scholar 

  15. Shak S. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Semin Oncol. 1999;26(Suppl 12):71–7.

    PubMed  Google Scholar 

  16. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–84.

    PubMed  Google Scholar 

  17. Cheung MC, Haynes AE, Meyer RM, Stevens A, Imrie KR, Members of the Hematology, Disease Site Group of the Cancer Care Ontario Program in Evidence-Based Care. Rituximab in lymphoma: a systematic review and consensus practice guidelines for cancer care Ontario. Cancer Treat Rev. 2007;33:161–76.

    PubMed  Google Scholar 

  18. Fabi A, De Laurentiis M, Caruso M, Valle E, Moscetti L, Santini D, et al. Efficacy and safety of T-DM1 in the ‘common-practice’ of HER2+ advanced breast cancer setting: a multicenter study. Oncotarget. 2017;8:6481–9.

    Google Scholar 

  19. Mondello P, Cuzzocrea S, Navarra M, Mian M. 90 Y-ibritumomab tiuxetan: a nearly forgotten opportunity. Oncotarget. 2016;7:7597–609.

    PubMed  Google Scholar 

  20. Keating GM. Bevacizumab: a review of its use in advanced cancer. Drugs. 2014;74:1891–925.

    PubMed  Google Scholar 

  21. Acúrcio RC, Scomparin A, Conniot J, Salvador JAR, Satchi-Fainaro R, Florindo HF, Cardos Guedes R. Structure-function analysis of immune checkpoint receptors to guide emerging anticancer immunotherapy. J Med Chem. 2018; https://doi.org/10.1021/acs.jmedchem.8b00541. [Epub ahead of print].

  22. Mahoney KM, Freeman GJ, McDermott DF. The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma. Clin Ther. 2015;37:764–82.

    PubMed  PubMed Central  Google Scholar 

  23. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.

    PubMed  PubMed Central  Google Scholar 

  24. Menaria J, Kitawat S, Verma V. Cancer vaccine: an overview. SJAMS. 2013;1:161–71.

    Google Scholar 

  25. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cell for acute lymphoid leukaemia. N Engl J Med. 2013;368:1509–18.

    PubMed  PubMed Central  Google Scholar 

  26. Ramos CA, Heslop HE, Brenner MK. CAR-T cell therapy for lymphoma. Annu Rev Med. 2016;67:165–83.

    PubMed  Google Scholar 

  27. The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991;324:1685–90.

    Google Scholar 

  28. Pignon JP, le Maitre A, Maillard E, Bourhis J, Group M-NC. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92:4–14.

    PubMed  Google Scholar 

  29. Ribassin-Majed L, Marguet S, Lee AWM, Ng WT, Ma J, Chan ATC, et al. What is the best treatment in nasopharyngeal carcinoma? An individual patient data network meta-analysis. J Clin Oncol. 2016;35:498–505.

    PubMed  PubMed Central  Google Scholar 

  30. Vishak S, Rangarajan B, Kekatpure VD. Neoadjuvant chemotherapy in oral cancers: selecting the right patients. Indian J Med Paediatr Oncol. 2015;36:148–53.

    PubMed  PubMed Central  Google Scholar 

  31. Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357:1705–15.

    PubMed  Google Scholar 

  32. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357:1695–704.

    PubMed  Google Scholar 

  33. Camille N, Rozehnal J, Roy E, Uczkowski D, Olson A, Genden E, et al. A phase I study of cabazitaxel in combination with platinum and 5-fluorouracil (PF) in locally advanced squamous cell carcinoma of head and neck (LA-SCCHN). Oral Oncol. 2017;71:99–104.

    PubMed  Google Scholar 

  34. Cohen EE, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, et al. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014;32:2735–43.

    PubMed  PubMed Central  Google Scholar 

  35. Haddad R, O’Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol. 2013;14:257–64.

    PubMed  Google Scholar 

  36. Lefebvre JL, Pointreau Y, Rolland F, Alfonsi M, Baudoux A, Sire E, et al. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomised phase II study. J Clin Oncol. 2013;31:853–9.

    PubMed  Google Scholar 

  37. Vermorken JB, Mesia R, Rivera F, Remenar E, Kaewecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116–27.

    PubMed  Google Scholar 

  38. Chang PM, Lu HJ, Wang LW, Tai SK, Chen MH, Chu PY, et al. Effectiveness of incorporating cetuximab into docetaxel/cisplatin/fluorouracil induction chemotherapy and chemoradiotherapy for inoperable squamous cell carcinoma of the oral cavity: a phase II study. Head Neck. 2017;39:1333–42.

    PubMed  Google Scholar 

  39. Specenier PM, Remenar E, Buter J, Schriivers DL, Bergamini C, Licitra LF, et al. TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial. Ann Oncol. 2017;28:2219–24.

    PubMed  Google Scholar 

  40. Bauml J, Selwert TY, Pfister F, Worden F, Liu J, Gilbert J, et al. Pembrolizumab for platinum—and cetuximab-refractory head and neck cancer: results from a single-arm phase II study. J Clin Oncol. 2017;35:1542–9.

    PubMed  PubMed Central  Google Scholar 

  41. Šeparovic R, Pavlovic M, Silovski T, Tecic Vuger M, Juric A. Systemic therapy of head and neck carcinoma. Lib Oncol. 2016;44:45–9.

    Google Scholar 

  42. Juloori A, Koyfman SA, Geiger JL, Joshi NP, Woody NM, Burkey BB, et al. Definitive chemoradiation in locally advanced squamous cell carcinoma of the hypopharynx: long-term outcomes and toxicity. Anticancer Res. 2018;38:3543–9.

    PubMed  Google Scholar 

  43. Lee SY, Choi YS, Song I-C, Park SJ, Keam B, Yang YJ, et al. Comparison of standard-dose 3-weekly cisplatin for concurrent chemoradiation of patients with locally advanced head and neck squamous cell cancer: a multicentre retrospective analysis. Medicine. 2018;97:810778. https://doi.org/10.1097/MD.0000000000010778.

    CrossRef  Google Scholar 

  44. Rades D, Seidl D, Janssen S, Bajrovic A, Hakim SG, Wollenberg B, Schild SE. Do we need 5-FU in addition to cisplatin for chemoradiation of locally advanced head- and-neck cancer? Oral Oncol. 2016a;57:40–5.

    PubMed  Google Scholar 

  45. Rades S, Strojan P, Sedl D, Janssen S, Bajorvic A, Kazic N, et al. Radiochemotherapy for locally advanced squamous cell carcinoma of the head and neck: higher-dose cisplatin every 3 weeks versus cisplatin/5-fluorouracil every 4 weeks. J Craniomaxillofac Surg. 2016b;44:1436–40.

    PubMed  Google Scholar 

  46. Nagasaka M, Zak M, Issa M, Kim H, Abrams J, Sukari A. Definitive chemoradiotherapy with carboplatin for squamous cell carcinoma of the head and neck. Laryngoscope. 2017;127:2260–4.

    PubMed  PubMed Central  Google Scholar 

  47. Nakahara S, Hanamoto A, Seo Y, Miyaguchi S, Yamaoto Y, Tomiyama Y, et al. Chemoradiotherapy with weekly low-dose docetaxel and cisplatin concurrent with radiation for patients with locally advanced nasopharyngeal carcinoma, followed by adjuvant chemotherapy for selected patients. Jpn J Clin Oncol. 2016;46:903–10.

    PubMed  Google Scholar 

  48. Mitsudo K, Toshiyuki K, Iida M, Iwai T, Nakashima H, Oguri S, et al. Retrograde superselective intra-arterial chemotherapy and daily concurrent radiotherapy for stage III and IV oral cancer: analysis of therapeutic results in 112 cases. Radiother Oncol. 2014;111:306–10.

    PubMed  Google Scholar 

  49. Geoffrois L, Martin L, De Raucourt D, Sun XS, Tao Y, Maingon P, et al. Induction chemotherapy followed by cetuximab radiotherapy is not superior to concurrent chemoradiotherapy for head and neck carcinomas: results of the GORTEC 2007-02 Phase III randomized trial. J Clin Oncol. 2018; https://doi.org/10.1200/JCO.2017.76.2591. [Epub before print].

  50. Barney CL, Walson S, Zamora P, Healy EH, Nolan N, Diavolitsis VM, et al. Clinical outcomes and prognostic factors in cisplatin versus cetuximab chemoradiation for locally advanced p16 positive oropharyngeal carcinoma. Oral Oncol. 2018;79:9–14.

    PubMed  Google Scholar 

  51. Rischin D, Peters LJ, O’Sullivan B, Giralt J, Fisher R, Yuen K, et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART0): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol. 2010;28:2989–95.

    PubMed  Google Scholar 

  52. Iocca O, Farcomeni A, Di Rocco A, Di Maio P, Golusinski P, Pardinas Lopez S, et al. Locally advanced squamous cell carcinoma of the head and neck: a systematic review and Bayesian network meta-analysis of the currently available treatment options. Oral Oncol. 2018;80:40–51.

    PubMed  Google Scholar 

  53. Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefevbre JL, Greiner RH, et al. Post-operative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350:1945–52.

    PubMed  Google Scholar 

  54. Cooper JS, Pajak TF, Forastierre AA, Jacobs J, Campbell BH, Saxsman SB, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350:1937–44.

    PubMed  Google Scholar 

  55. Cooper JS, Zhang Q, Pajak TF, Forastierre AA, Jacobs J, Saxman SB, et al. Long-term follow-up of the RTOG 9501/Intergroup phase II trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2012;84:1198–205.

    PubMed  PubMed Central  Google Scholar 

  56. Kirke DN, Qureshi MM, Kamran SC, Ezzat W, Jalisi S, Salama A, et al. Role of adjuvant chemoradiotherapy in T4N0 stage IV head and neck cancer: a national Cancer Database analysis. Head Neck. 2018;40:1174–84.

    PubMed  Google Scholar 

  57. Franchin G, Minatel E, Politi D, Gobitti C, Talamini R, Vaccher E, et al. Postoperative reduced dose of cisplatin concomitant with radiation therapy in high-risk head and neck squamous cell carcinoma. Cancer. 2009;115:2464–71.

    PubMed  Google Scholar 

  58. Harari PM, Harris J, Kies MS, Myers JN, Jordan RC, Gillison ML, et al. Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234. J Clin Oncol. 2014;32:2486–95.

    PubMed  PubMed Central  Google Scholar 

  59. Araki D, Redman MW, Martins R, Eaton K, Baik C, Chow L, et al. Concurrent cetuximab and postoperative radiation in resected high-risk squamous cell carcinomas of the head and neck: a single-institution experience. Head Neck. 2016;38:1318–23.

    PubMed  Google Scholar 

  60. Harrington K, Temam S, Mehanna H, D’Cruz A, Jain M, D’onofrio I, et al. Postoperative adjuvant lapatinib and concurrent chemoradiotherapy followed by maintenance lapatinib monotherapy in high-risk patients with resected squamous cell carcinoma of the head and neck: a phase III, randomized, double-blind, placebo-controlled study. J Clin Oncol. 2015;33:4202–9.

    PubMed  Google Scholar 

  61. Tam M, Wu SP, Gerber NK, Lee A, Schreiber D, Givi B, Hu K. The impact of adjuvant chemoradiotherapy timing on survival of head and neck cancers. Laryngoscope. 2018; https://doi.org/10.1002/lary.27.152. [Epub before print].

  62. Zenga J, Gross J, Fowler S, Chen J, Vila P, Richmon JD, et al. Salvage of recurrence after surgery and adjuvant therapy: a systematic review. Am J Otolaryngol. 2018;39:223–7.

    PubMed  Google Scholar 

  63. Civantos FJ, Karakullukcu B, Biel M, Silver CE, Rinaldo A, Saba NF, et al. A review of photodynamic therapy for neoplasms of the head and neck. Adv Ther. 2018;35:324–40.

    PubMed  Google Scholar 

  64. Vander Poorten V, Meulemans J, Nuyts S, Clement P, Hermans R, Hauben E, Delaere P. Postoperative photodynamic therapy as a new adjuvant treatment after robot-assisted salvage surgery of recurrent squamous cell carcinoma of the base of tongue. World J Surg Oncol. 2015;13:214–8.

    PubMed  PubMed Central  Google Scholar 

  65. Spencer SA, Harris J, Wheeler RH, Machtay M, Schultz C, Spanos W, et al. Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck. 2008;30:21–8.

    Google Scholar 

  66. Morton RP, Rugman F, Dorman EB, Stoney PJ, Wilson JA, McCormick M, et al. Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial. Cancer Chemother Pharmacol. 1985;15:283–9.

    PubMed  Google Scholar 

  67. Eisenberger M, Hornedo J, Silva H, Donehower R, Spaulding M, Van Echo D. Carboplatin (NSC-241-240): an active platinum analog for the treatment of squamous-cell carcinoma of the head and neck. J Clin Oncol. 1986;4:1506–9.

    PubMed  Google Scholar 

  68. Sharma M, Gupta M, Fotedar V, Sharma A. Methotrexate, an attractive agent for palliation in head and neck cancers. South Asian J Cancer. 2014;3:299.

    Google Scholar 

  69. Jacobs C, Lyman G, Velez-Garcai E, Sridhar KS, Knight W, Hochster H, et al. A phase II randomised study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 1992;10:257–63.

    PubMed  Google Scholar 

  70. Dreyfus AI, Clark JR, Norris CM, Rossi RM, Lucarini JW, Busse PM, et al. Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol. 1996;14:1672–8.

    Google Scholar 

  71. Gibson MK, Li Y, Murphy B, Hussain MH, DeConti RC, Ensley J, et al. Randomised phase II evaluation of cisplatin plus fluorouracil versus cisplatin in advanced head and neck cancer (E1359): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;20:3562–7.

    Google Scholar 

  72. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA, Eastern Cooperative Oncology Group. Phase III randomised trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2005;23:8646–54.

    PubMed  Google Scholar 

  73. Vermorken JB, Stöhlmacher-Williams J, Davidenko I, Licitra L, Winquist E, Villanueva C, et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECRUM): an open-label phase 3 randomised trial. Lancet Oncol. 2013;14:697–710.

    PubMed  Google Scholar 

  74. Machiels JP, Subramanian S, Ruzsa A, Repassy G, Lifirenko I, Flyglare A, et al. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. Lancet Oncol. 2011;12:333–43.

    PubMed  Google Scholar 

  75. Jimenca A, Machiels JP, Wirth L, Specenier P, Seiwert TY, Mardiuadi F, et al. Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluoruracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck. Cancer. 2016;122:3803–11.

    Google Scholar 

  76. Siu LL, Soulieres D, Chen EX, Pond GR, Chin SF, Francis P, et al. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. A Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Trials Group Study. J Clin Oncol. 2007;25:2178–83.

    PubMed  Google Scholar 

  77. Argiris A, Karamouzis MV, Gooding WE, Bransletter BF, Zhong S, Raez LE, et al. Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. J Clin Oncol. 2011;29:1140–5.

    PubMed  PubMed Central  Google Scholar 

  78. Fury MG, Lee NY, Sherman E, Ho AL, Rao S, Heguy A, et al. A phase I study of everolimus + weekly cisplatin + intensity modulated radiation therapy in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2013;87:479–86.

    PubMed  Google Scholar 

  79. Dunn LA, Fury MG, Xiao H, Baxi SS, Sherman EJ, Korte S, et al. A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Ann Oncol. 2017;28:2533–8.

    PubMed  PubMed Central  Google Scholar 

  80. Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856–67.

    PubMed  PubMed Central  Google Scholar 

  81. Gillison ML, Blumenschein GR, Fayette J, Guijay J, Coeva AD, Licitra L, et al. CheckMate 141: 1-year update and subgroup analysis of nivolumab as first-line therapy in patients with recurrent/metastatic head and neck cancer. Oncologist. 2018; https://doi.org/10.1634/theoncologist.2017-0674.

  82. Chow LQ, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, et al. Antitumour activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol. 2016;34:3838–45.

    PubMed  PubMed Central  Google Scholar 

  83. Cohen EE, Harrington KJ, Le Tourneau C, Dinis J, Licitra L, Ahn M-J, et al. Pembrolizumab (pembo) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): phase III KEYNOTE-040 trial. Ann Oncol. 2017;28(Suppl 5) https://doi.org/10.1093/annonc/mdx440.040.

  84. Dietsch GN. Motolimod effectively drives immune function activation in advanced cancer patients. Oncoimmunology. 2016; https://doi.org/10.1080/2162402X.2015.1126037.

  85. Ferris RL, Saba NF, Gitilitz BJ, Haddad R, Sukari A, Neupane P, et al. Effect of adding motolimod to standard combination chemotherapy and cetuximab treatment of patients with squamous cell carcinoma of the head and neck: The active8 randomised clinical trial. JAMA Oncol. 2018; https://doi.org/10.1001/jamaoncol.2018.1888. [Epub before print].

  86. Specenier P, Vermorken JB. Optimizing treatments for recurrent or metastatic head and neck squamous cell carcinoma. Expert Rev Anticancer Ther. 2018; https://doi.org/10.1080/14737140.2018.1493925.

  87. Stewat JS, Cohen EE, Licitra L, Van Herpen CM, Khorprasert C, Soulieres D, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol. 2009;27:1864–71.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Oncology, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA, Australia

    Ian Olver

Authors
  1. Ian Olver
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Oral Medicine and Oral Oncology, Griffith University, QLD, Australia

    Prof. Raj Nair

Rights and permissions

Reprints and Permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this chapter

Verify currency and authenticity via CrossMark

Cite this chapter

Olver, I. (2022). Solid Tumours and Update on Modern Medical Oncology Interventions. In: Nair, R. (eds) Orofacial Supportive Care in Cancer . Springer, Cham. https://doi.org/10.1007/978-3-030-86510-8_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-86510-8_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-86509-2

  • Online ISBN: 978-3-030-86510-8

  • eBook Packages: MedicineMedicine (R0)